An Autonomous Implantable Device for the Prevention of Death from Opioid Overdose
Joanna L. CiattiiD, Abraham Vázquez‐GuardadoiD, Victoria E. BringsiD, Jihun ParkiD, Brian C. RuyleiD, Rebecca A. OberiD, Alicia J. McLuckieiD, Michael TalcottiD, Emily A. CarteriD, Amy R. BurrelliD, Rebecca A. Sponenburg, Jacob T. TruebiD, Prashant GuptaiD, Joohee KimiD, Raudel O. AvilaiD, Minho SeongiD, Richard A. SlivickiiD, Melanie A. Kaplan, Bryan Villalpando-HernandeziD, Nicolas MassalyiD, Michael C. MontanaiD, Mitchell A. PetiD, Yonggang Y. HuangiD, José A. MoróniD, Robert W. GereauiD, John A. RogersiD
Abstract
Opioid overdose accounts for nearly 75,000 deaths per year in the United States, representing a leading cause of mortality amongst the prime working age population (25-54 years). At overdose levels, opioid-induced respiratory depression becomes fatal without timely administration of the rescue drug naloxone. Currently, overdose survival relies entirely on bystander intervention, requiring a nearby person to discover and identify the overdosed individual, and have immediate access to naloxone to administer. Government efforts have focused on providing naloxone in abundance but do not address the equally critical component for overdose rescue: a willing and informed bystander. To address this unmet need, we developed the Naloximeter: a class of life-saving implantable devices that autonomously detect and treat overdose, with the ability to simultaneously contact first-responders. We present three Naloximeter platforms, for both fundamental research and clinical translation, all equipped with optical sensors, drug delivery mechanisms, and a supporting ecosystem of technology to counteract opioid-induced respiratory depression. In small and large animal studies, the Naloximeter rescues from otherwise fatal opioid overdose within minutes. This work introduces life-changing, clinically translatable technologies that broadly benefit a susceptible population recovering from opioid use disorder.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 30
- FWCI
- 10.35
- Field percentile
- top 1%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The NMDAR positive allosteric modulator NYX-783 selectively blocks opioid withdrawal conditioned place aversion in mice.
Richard Trinko, Ethan P. Foscue, … Ralph Dileone·bioRxiv·Sep 25, 2025
- Whole Body PBPK Model of Nasal Naloxone Administration to Measure Repeat Dosing Requirements During Fentanyl Overdose
A. Baird, S. A. White, … E. Bisgaard·bioRxiv·Apr 24, 2023
- Oxytocin treats respiratory depression and reduces mortality from fentanyl and the combination of xylazine-fentanyl
Joan B. Escobar, John Wainwright, … David Mendelowitz·bioRxiv·Feb 24, 2026
- Proof of Concept for High-Dose Cannabidiol Pretreatment to Antagonize Opioid Induced Persistent Apnea
Beth M. Wiese, Evgeny Bondarenko, Jack L. Feldman·Frontiers in NeurosciencePeer-reviewed·Oct 8, 2025
- Melanocortin receptor 4 agonist setmelanotide treats opioid-induced respiratory depression
Mateus R. Amorim, Noah R Williams, … Vsevolod Y. Polotsky·bioRxiv·Mar 10, 2026
- Negative allosteric modulation of the μ-opioid receptor
E. S. O'Brien, V. A. Rangari, … B. K. Kobilka·bioRxiv·Sep 8, 2023